Clinical Trial

Psilocybin Microdosing on Cognition, Mood and Quality of Life

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo. Investigators hypothesize that compared to placebo, 30 days of intermittently microdosed psilocybin will produce observable changes in mood, cognition, subjective well-being and MRI, in the absence of psychedelic experiences.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-04-01
Trial Details
NCT Number NCT07449351
Lead Sponsor Yale University
Collaborators: Hartford HealthCare
Conditions Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Enrollment 20 participants
Start Date 2026-08-10
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-23